# Optiscan Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/optiscan-biomedical

- Industry: Medical Devices & Equipment
- Headquarters: Hayward, US
- Website: www.optiscancorp.com
- Total disclosed funding: $108M
- Latest round: Series D (Jan 25, 2013)
- Investors on record: 16

## About

Optiscan Biomedical Corp. focuses on developing advanced imaging technologies for medical applications, particularly in the fields of pathology and oncology, enhancing diagnostic accuracy and patient care.Founded in 1994 and headquartered in Hayward, US, Optiscan Biomedical Corp. specializes in medical imaging solutions. The company has successfully secured a total of USD 20.00 mn from 11 funding deals, with the latest being a Series E round in March 2019. The company is led by CEO Peter Rule.Optiscan Biomedical Corp. provides innovative imaging technologies designed to improve diagnostics in medical settings. Their flagship products include advanced imaging systems tailored for pathology and oncology, enabling healthcare professionals to utilize high-resolution images for accurate diagnoses. The services cater primarily to hospitals and laboratories, enhancing clinical workflows and patient outcomes.The company generates revenue through the sale of its imaging systems and related services to healthcare institutions. While specific pricing structures for these offerings are not publicly disclosed, the business model supports direct sales to medical facilities, facilitating enhanced diagnostic processes.In March 2019, Optiscan Biomedical Corp. raised USD 20 mn in Series E funding, which will be utilized to accelerate the development of new imaging products aimed at expanding their market presence. The company is planning to launch several innovative imaging solutions by the end of 2022, targeting growth in both domestic and international markets, particularly in Asia and Europe, where demand for advanced medical imaging technologies continues to rise.

## Funding rounds

- Series D, Jan 25, 2013, $31M — MedVenture Associates, Morgenthaler Ventures, Wexford Capital
- Series C, Apr 9, 2010, $32M — MedVenture Associates, Wexford Capital, Hercules Capital
- Series B, Sep 25, 2008, $5M — Morgenthaler Ventures, Prism Venture Management, Wexford Capital, NGN Capital, EGS Healthcare Capital Partners, Signet Healthcare Partners, MedVenture Partners
- Series B, Oct 3, 2005, $36M — MedVenture Associates, Morgenthaler Ventures, Prism Venture Management, Wellcome Trust, Houston Ventures, Mitsui Global Investment, NGN Capital, EGS Healthcare Capital Partners, Ascension Ventures
- Series B, Oct 27, 1999, $5M — Brentwood Associates, Zesiger Capital Group, JP Morgan Asset Management

## Investors

- Brentwood Associates (https://capitalatlas.ai/funds/brentwood-associates) — Series B
- Zesiger Capital Group (https://capitalatlas.ai/funds/zesiger-capital-group) — Series B
- JP Morgan Asset Management (https://capitalatlas.ai/funds/jp-morgan-asset-management) — Series B
- MedVenture Associates (https://capitalatlas.ai/funds/medventure-associates) — Series B, Series C, Series D
- Morgenthaler Ventures (https://capitalatlas.ai/funds/morgenthaler-ventures) — Series B, Series D
- Prism Venture Management (https://capitalatlas.ai/funds/prism-venture-management) — Series B
- Wellcome Trust — Series B
- Houston Ventures (https://capitalatlas.ai/funds/houston-ventures) — Series B
- Mitsui Global Investment (https://capitalatlas.ai/funds/mitsui-global-investment) — Series B
- NGN Capital (https://capitalatlas.ai/funds/ngn-capital) — Series B
- EGS Healthcare Capital Partners (https://capitalatlas.ai/funds/egs-healthcare-capital-partners) — Series B
- Ascension Ventures (https://capitalatlas.ai/funds/ascension-ventures) — Series B
- Wexford Capital — Series B, Series C, Series D
- Signet Healthcare Partners (https://capitalatlas.ai/funds/signet-healthcare-partners) — Series B
- MedVenture Partners (https://capitalatlas.ai/funds/medventure-partners) — Series B
- Hercules Capital (https://capitalatlas.ai/funds/hercules-capital) — Series C